Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage biopharmaceutical firm focused on developing monoclonal antibodies for the treatment of autoimmune diseases. The company is dedicated to enabling normal lives for patients with these conditions. Their primary product candidate, IMVT-1401, is a fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (FcRn). IMVT-1401 is currently in Phase IIa clinical trials for treating myasthenia gravis and thyroid eye disease, with additional trials for warm autoimmune hemolytic anemia underway.
Immunovant is also developing batoclimab and IMVT-1402, which target the same FcRn receptor to modulate the immune response. The company has recently announced promising initial Phase 1 data for IMVT-1402, showing significant IgG reduction with minimal changes in serum albumin and LDL cholesterol, pointing towards a potential best-in-class profile. With a robust pipeline and strategic partnerships, including being a subsidiary of Roivant Sciences Ltd., Immunovant is well-positioned in the biopharmaceutical sector.
Recent financial highlights underline the company's growth, with significant net proceeds from public offerings and private placements. For the fiscal quarter ended September 30, 2023, research and development expenses were $48.0 million, primarily due to the development of IMVT-1402.
In corporate updates, Immunovant recently completed a public offering and concurrent private placement, raising approximately $467 million. The company continues to expand its clinical trials and has announced plans to initiate several potentially registrational programs for IMVT-1402 by March 31, 2025. With ongoing advancements in their clinical programs and financial strength, Immunovant, Inc. stands at the forefront of innovative treatments for autoimmune diseases.
Immunovant (Nasdaq: IMVT) reported a net loss of $63.2 million, or $0.49 per share, for Q3 FY2022, compared to a loss of $41.4 million, or $0.36 per share, in Q3 FY2021. Cash reserves stood at approximately $433 million, expected to fund operations through 2025. The company initiated a Phase 3 trial for batoclimab in thyroid eye disease and a pivotal Phase 2b trial in chronic inflammatory demyelinating polyneuropathy. A Phase 1 trial for IMVT-1402 is expected to begin in early 2023. Investors anticipate multiple data readouts starting mid-2023, potentially enhancing the company’s position in autoimmune therapies.
Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company, announced that CEO Pete Salzmann, M.D., will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, at 3:55 pm Eastern Time. The webcast will be accessible through the company's Investor Relations section. Immunovant focuses on developing therapies for autoimmune diseases, particularly with FcRn inhibitor technology, addressing significant patient needs.
Immunovant, a clinical-stage biopharmaceutical company, reported key developments and financial results for Q2 fiscal 2022. The company introduced IMVT-1402, a next-generation FcRn inhibitor demonstrating promising results in IgG reduction. New programs for batoclimab targeting chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves' disease were announced, with pivotal trials expected soon. Financially, Immunovant's R&D expenses rose to $37.7 million, and the company posted a net loss of $47.9 million. With a pro forma cash balance of $476 million, the cash runway is projected to extend into H2 2025.
Immunovant, Inc. (Nasdaq: IMVT) announced an underwritten offering of 12,500,000 common stock shares priced at $6.00 each, expected to yield $75 million before expenses. This capital will help fund the development of IMVT-1402 and support a pivotal trial. The company anticipates that its current cash, combined with proceeds from this offering, will sustain operations through mid-2025. The offering will close around October 6, 2022, subject to standard conditions. SVB Securities and Truist Securities are the joint bookrunning managers.
Immunovant, Inc. (Nasdaq: IMVT) announced the development of IMVT-1402, an anti-FcRn therapy, at Roivant’s Investor Day on September 28, 2022. The company plans to submit an IND and start a Phase 1 study in early 2023, with initial results expected mid-year. IMVT-1402 shows potential for deep IgG reduction with minimal impact on albumin and LDL based on animal studies. The asset's composition patent is anticipated to provide protection until at least 2042, complementing the existing batoclimab program, which continues to advance in parallel.
On September 21, 2022, Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate update at Roivant’s Investor Day on September 28, 2022, at 11:15 AM ET. The event will include a webcast available on the company's website. Immunovant focuses on developing therapies for autoimmune diseases and is known for its investigational compound, batoclimab, a monoclonal antibody targeting FcRn. The company aims to meet significant unmet patient needs in this sector.
Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced that CEO Pete Salzmann will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The chat is scheduled for September 14 at 4:00 PM Eastern Time. Interested parties can access the presentation via a webcast on the company’s website. Immunovant is developing innovative therapies, including the investigational compound batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn).
Immunovant (Nasdaq: IMVT) plans to initiate a pivotal Phase 2b trial for batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in late 2022, with expected results from an open-label period by early 2024. A Phase 2 trial for Graves’ Disease is set for early 2023, with results anticipated later that year. The company expects a steady stream of clinical data every six months from late 2023 through early 2025, encompassing multiple indications. Immunovant continues to pursue batoclimab's development across five autoimmune conditions.
Immunovant, Inc. (Nasdaq: IMVT) has announced plans to advance the development of batoclimab for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Graves' Disease. A pivotal Phase 2b trial for CIDP is set to begin in late 2022, with initial results from an open-label period expected in early 2024. A Phase 2 trial for Graves’ Disease will start in early 2023, with results anticipated in late 2023. Immunovant aims for regular clinical data readouts every six months from late 2023 to early 2025, covering multiple indications, including Myasthenia Gravis and Thyroid Eye Disease.
FAQ
What is the current stock price of Immunovant (IMVT)?
What is the market cap of Immunovant (IMVT)?
What does Immunovant, Inc. specialize in?
What is IMVT-1401?
Where is Immunovant, Inc. headquartered?
Is Immunovant, Inc. a subsidiary of another company?
What are some of the recent achievements of Immunovant, Inc.?
How is Immunovant, Inc. funded?
What are the future plans for IMVT-1402?
What is the financial condition of Immunovant, Inc.?
What is batoclimab?
Who are the key management figures at Immunovant, Inc.?
